Key result
Glibenclamide accelerated the inactivation time-course of the total outward current in human atrial myocytes, reducing tau(fast) from 12.7 to 5.8 ms.
Why the study?
Does glibenclamide inhibit voltage-dependent potassium currents in human atrial and ventricular myocytes?
Does glibenclamide inhibit voltage-dependent potassium currents in human atrial and ventricular myocytes?
Glibenclamide inhibits voltage-dependent cardiac potassium currents, specifically Ito1 and IKur, in human atrial and ventricular myocytes at concentrations above 10 microM.
Answers are grounded in this paper and cite their sources.
May alter atrial repolarization at high doses; hypothesis-generating for sulfonylurea effects on human cardiac K+ currents.
1 It was the aim of our study to investigate the effects of the sulphonylurea glibenclamide on voltage dependent potassium currents in human atrial myocytes. 2 The drug blocked a fraction of the quasi steady state current (ramp response) which was activated positive to -20 mV, was sensitive to 4-aminopyridine (500 microM) and was different from the ATP dependent potassium current IK(ATP). 3 Glibenclamide dose dependently inhibited both, the peak as well as the late current elicited by step depolarization positive to -20 mV. The IC50 for reduction in charge area of total outward current was 76 microM. 4 The double-exponential inactivation time-course of the total outward current was accelerated in the presence of glibenclamide with a tau(fast) of 12.7+/-1.5 ms and a tau(slow) of 213+/-25 ms in control and 5.8+/-1.9 ms (P<0.001) and 101+/-20 ms (P<0.05) under glibenclamide (100 microM). 5 Our data suggest, that both repolarizing currents in human atrial myocytes, the transient outward current (Ito1) and the ultrarapid delayed rectifier current (IKur) were inhibited by glibenclamide. 6 In human ventricular myocytes glibenclamide inhibited Ito1 without affecting the late current. 7 Our data suggest that glibenclamide inhibits human voltage dependent cardiac potassium currents at concentrations above 10 microM.
No takes yet. Share an insight, caveat, or question.
Schäffer et al. (1999) studied this question. Glibenclamide vs. Control was evaluated on tau(fast) of the total outward current inactivation time-course (p=<0.001). Glibenclamide accelerated the inactivation time-course of the total outward current in human atrial myocytes, reducing tau(fast) from 12.7 to 5.8 ms.
Synapse has enriched 10 related papers. Consider them for comparative context: